Skip to main content
Top
Published in: Journal of Gastroenterology 12/2017

01-12-2017 | Original Article—Liver, Pancreas, and Biliary Tract

Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury

Authors: Kei Morio, Michio Imamura, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuki Nakamura, Tomoki Kobayashi, Takashi Nakahara, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Yoshiiku Kawakami, Hiroshi Aikata, Clair Nelson Hayes, Kazuko Tsugawa, Michiya Yokozaki, Kazuaki Chayama

Published in: Journal of Gastroenterology | Issue 12/2017

Login to get access

Abstract

Background

Wisteria floribunda agglutinin positive human Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum glycomarker for liver fibrosis. However, it is not known whether or not M2BPGi reflects only liver fibrosis. We measured serum M2BPGi levels in patients with acute liver injury.

Methods

Fifty-one patients with acute liver injury were enrolled. M2BPGi levels were measured at the initial visit and at achievement of recovery. The relationship between M2BPGi values at the initial visit and clinical outcomes was analyzed.

Results

Serum M2BPGi levels at the initial visit were elevated in 47 of 51 acute liver injury patients (8.33 ± 7.56 cutoff index). M2BPGi values were associated with prothrombin activity (r = −0.600, P = 0.001), total bilirubin level (r = 0.588, P = 0.001), and Model for End-Stage Liver Disease score (r = 0.490, P = 0.001) but not with aspartate aminotransferase (r = −0.070) and alanine aminotransferase (r = −0.073) levels. M2BPGi values at the initial visit were significantly higher in patients with acute liver failure (diagnosed by prothrombin activity of 40% or less; P < 0.001), subsequent development of hepatic coma (P = 0.036), and subsequent requirement of liver transplant (P = 0.014), and in a patient who died (P = 0.045). M2BPGi values decreased after aminotransferase level normalization in patients who recovered from acute liver injury; however, M2BPGi level was not a predictive factor for recovery with medical therapy.

Conclusions

Serum M2BPGi values increased in patients with acute liver injury and decreased following recovery. The marker seems to reflect not only liver fibrosis but also other factors, such as liver inflammation, liver damage, and hepatocyte regeneration.
Literature
1.
go back to reference Mochida S, Nakayama N, Ido A, et al. Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: a report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015. Hepatol Res. 2016;46:369–71.CrossRefPubMed Mochida S, Nakayama N, Ido A, et al. Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: a report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015. Hepatol Res. 2016;46:369–71.CrossRefPubMed
3.
go back to reference Kumar R, Shalimar Bhatia V, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665–74.CrossRefPubMed Kumar R, Shalimar Bhatia V, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665–74.CrossRefPubMed
4.
go back to reference Mochida S, Nakayama N, Matsui A, et al. Re-evaluation of the guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res. 2008;38:970–9.CrossRefPubMed Mochida S, Nakayama N, Matsui A, et al. Re-evaluation of the guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res. 2008;38:970–9.CrossRefPubMed
5.
go back to reference Naiki T, Nakayama N, Mochida S, et al. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: application to indication criteria for liver transplantation. Hepatol Res. 2012;42:68–75.CrossRefPubMed Naiki T, Nakayama N, Mochida S, et al. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: application to indication criteria for liver transplantation. Hepatol Res. 2012;42:68–75.CrossRefPubMed
6.
go back to reference Nakayama N, Oketani M, Kawamura Y, et al. Algorithm to determine the out come of patients with acute liver failure: a data-mining analysis using decision trees. J Gastroenterol. 2012;47:664–77.CrossRefPubMedPubMedCentral Nakayama N, Oketani M, Kawamura Y, et al. Algorithm to determine the out come of patients with acute liver failure: a data-mining analysis using decision trees. J Gastroenterol. 2012;47:664–77.CrossRefPubMedPubMedCentral
7.
go back to reference Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–61.CrossRefPubMedPubMedCentral Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–61.CrossRefPubMedPubMedCentral
8.
go back to reference Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.CrossRefPubMedPubMedCentral Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.CrossRefPubMedPubMedCentral
9.
go back to reference Abe M, Miyake T, Kuno A, et al. Association between Wisteria floriunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015;50:776–84.CrossRefPubMed Abe M, Miyake T, Kuno A, et al. Association between Wisteria floriunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015;50:776–84.CrossRefPubMed
10.
go back to reference Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 2015;110:857–64.CrossRefPubMed Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 2015;110:857–64.CrossRefPubMed
11.
go back to reference Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563–70.CrossRefPubMedPubMedCentral Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563–70.CrossRefPubMedPubMedCentral
12.
go back to reference Fujiyoshi M, Kuno A, Gotoh M, et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol. 2015;50:1134–44.CrossRefPubMed Fujiyoshi M, Kuno A, Gotoh M, et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol. 2015;50:1134–44.CrossRefPubMed
13.
go back to reference Tamaki N, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res. 2015;45:E82–8.CrossRefPubMed Tamaki N, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res. 2015;45:E82–8.CrossRefPubMed
14.
go back to reference Hanai T, et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2-binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res. 2015;45:1083–90.CrossRefPubMed Hanai T, et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2-binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res. 2015;45:1083–90.CrossRefPubMed
15.
go back to reference Sasaki R, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One. 2015;10:e0129053.CrossRefPubMedPubMedCentral Sasaki R, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One. 2015;10:e0129053.CrossRefPubMedPubMedCentral
16.
go back to reference Nagata H, Nakagawa M, Nichimura-Sakurai Y, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016;10:956–64.CrossRefPubMed Nagata H, Nakagawa M, Nichimura-Sakurai Y, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016;10:956–64.CrossRefPubMed
17.
go back to reference Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.CrossRefPubMed Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.CrossRefPubMed
18.
go back to reference Umemura T, Tanaka E, Kiyosawa K, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52–6.CrossRefPubMed Umemura T, Tanaka E, Kiyosawa K, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52–6.CrossRefPubMed
Metadata
Title
Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury
Authors
Kei Morio
Michio Imamura
Kana Daijo
Yuji Teraoka
Fumi Honda
Yuki Nakamura
Tomoki Kobayashi
Takashi Nakahara
Yuko Nagaoki
Tomokazu Kawaoka
Masataka Tsuge
Akira Hiramatsu
Yoshiiku Kawakami
Hiroshi Aikata
Clair Nelson Hayes
Kazuko Tsugawa
Michiya Yokozaki
Kazuaki Chayama
Publication date
01-12-2017
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 12/2017
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1345-y

Other articles of this Issue 12/2017

Journal of Gastroenterology 12/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.